全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

新辅助化疗治疗进展期胃癌的疗效分析
The Efficacy Analysis in the Treatment of Advanced Gastric Cancer with Neoadjuvant Chemotherapy

DOI: 10.12677/ACM.2020.107207, PP. 1376-1382

Keywords: 胃癌，新辅助化疗，不良反应，病理完全缓解
Gastric Cancer, Neoadjuvant Chemotherapy, Adverse Reactions, Pathological Complete Response

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的：探讨进展期胃癌应用新辅助化疗的疗效及其安全性。方法：回顾性分析2013年1月至2019年2月间我收治的56例进展期胃癌患者临床资料，采用新辅助化疗，2个治疗周期后进行化疗疗效分析；并评估临床疗效和不良反应。结果：所有患者均顺利完成新辅助化疗(100%)，平均化疗周期为2.48 ± 0.15个周期，化疗方案有SOX方案、DOS方案和FLOT方案。本组病例中CR 3例(5.35%)，PR 30例(53.57%)，SD 15例(26.79%)，PD 8例(14.29%)，有效率58.93%。49例行根治性切除术，4例行姑息性切除术，3例因疾病进展未进行手术。化疗副反应主要有骨髓抑制、恶心呕吐、腹泻、肝功能损害、皮肤过敏。中位存活时间为23.5个月。结论：新辅助化疗疗效安全、副反应低，能给部分进展期胃癌患者带来生存获益。
Objective: To investigate the efficacy and safety of neoadjuvant chemotherapy for advanced gastric cancer. Methods: From January 2013 to February 2019, 56 patients with advanced gastric cancer who treated with neoadjuvant chemotherapy were retrospectively analyzed. The efficacy of chemotherapy was analyzed after 2 treatment cycles. Clinical efficacy and adverse reactions were evaluated. Results: All patients successfully completed neoadjuvant chemotherapy (100%) with an average chemotherapy cycle of 2.48 ± 0.15 cycles. The chemotherapy regimen included SOX regimen, DOS regimen and FLOT regimen. In this group, there were 3 cases of CR (5.35%), 30 cases of PR (53.57%), 15 cases of SD (26.79%), and 8 cases of PD (14.29%), with an effective rate of 58.93%. Forty-nine patients underwent radical resection, 4 underwent palliative resection, and 3 did not undergo surgery due to disease progression. The Side effects of chemotherapy mainly include myelosuppression, nausea and vomiting, diarrhea, liver damage, skin allergy. Median survival was 23.5 months. Conclusion: Neoadjuvant chemotherapy is safe and has low side effects. It can bring survival benefit to some patients with advanced gastric cancer.

References

[1]  Chen, W., Sun, K., Zheng, R., et al. (2018) Cancer Incidence and Mortality in China, 2014. Chinese Journal of Cancer Research, 30, 1-12.
https://doi.org/10.21147/j.issn.1000-9604.2018.01.01
[2]  Li, Z., Shan, F., Ying, X., et al. (2018) Laparoscopic or Open Distal Gastrectomy after Neoadjuvant Chemotherapy for Advanced Gastric Cancer: Study Protocol for a Randomised Phase II Trial. BMJ Open, 8, e021633.
https://doi.org/10.1136/bmjopen-2018-021633
[3]  Patel, S.H. and Kooby, D.A. (2011) Gastric Adenocarcinoma Surgery and Adjuvant Therapy. Surgical Clinics of North America, 91, 1039-1077.
https://doi.org/10.1016/j.suc.2011.06.009
[4]  Cunningham, D., Allum, W.H., Stenning, S.P., et al. (2006) Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. The New England Journal of Medicine, 355, 11-20.
https://doi.org/10.1056/NEJMoa055531
[5]  Ychou, M., Boige, V., Pignon, J.P., et al. (2011) Perioperative Chemotherapy Compared with Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. Journal of Clinical Oncology, 29, 1715-1721.
https://doi.org/10.1200/JCO.2010.33.0597
[6]  郗洪庆, 张珂诚, 卫勃, 等. 胃癌TNM分期第八版更新在临床诊断治疗中的意义和思考[J]. 中华胃肠外科杂志, 2017, 20(2): 166-170.
[7]  Japanese Gastric Cancer Association (2011) Japanese Classification of Gastric Carcinoma: 3rd English Edition. Gastric Cancer, 14, 101-112.
https://doi.org/10.1007/s10120-011-0041-5
[8]  Lawrence H Schwartz, Saskia Litière, Elisabeth de Vries, et al. (2016) RECIST 1.1-Update and Clarification: From the RECIST Committee. European Journal of Cancer, 62, 132-137.
https://doi.org/10.1016/j.ejca.2016.03.081
[9]  Hu, Y., Hu, D., Li, W. and Yu, X. (2019) Neoadjuvant Chemotherapy Brings More Survival Benefits than Postoperative Chemotherapy for Resectable Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials. JBUON, 24, 201-214.
[10]  Das, M. (2017) Neoadjuvant Chemotherapy: Survival Benefit in Gastric Cancer. The Lancet Oncology, 18, e307.
https://doi.org/10.1016/S1470-2045(17)30321-2
[11]  Eom, B.W., Kim, S., Kim, J.Y., et al. (2018) Survival Benefit of Perioperative Chemotherapy in Patients with Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis. Journal of Gastric Cancer, 18, 69-81.
https://doi.org/10.5230/jgc.2018.18.e9
[12]  Cho, H., Nakamura, J., Asaumi, Y., et al. (2015) Long-Term Survival Outcomes of Advanced Gastric Cancer Patients Who Achieved a Pathological Complete Response with Neoadjuvant Chemotherapy: A Systematic Review of the Literature. Annals of Surgical Oncology, 22, 787-792.
https://doi.org/10.1245/s10434-014-4084-9
[13]  Fujitani, K., Ajani, J.A., Crane, C.H., et al. (2007) Impact of Induction Chemotherapy and Properative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. Annals of Surgical Oncology, 14, 2010-2017.
https://doi.org/10.1245/s10434-006-9198-2
[14]  Kondo, K., Matsusaka, S., Ishihara, S., et al. (2019) Long-Term Results of a Multicenter Phase II Study of Preoperative Chemoradiotherapy with S-1 plus Oxaliplatin for Locally Advanced Rectal Cancer (JACCRO CC-04): SHOGUN Trial). Radiotherapy & Oncology, 134, 199-203.
https://doi.org/10.1016/j.radonc.2019.02.006
[15]  Wang, Y., Cheng, X., Cui, Y.H., et al. (2018) Efficacy after Preoperative Capecitabine and Oxaliplatin (XELOX) versus Docetaxel, Oxaliplatin and S1 (DOS) in Patients with Locally Advanced Gastric Adenocarcinoma: A Propensity Score Matching Analysis. BMC Cancer, 18, 702.
https://doi.org/10.1186/s12885-017-3767-6
[16]  Al-Batran, S.E., Homann, N., Pauligk, C., et al. (2019) Perioperative Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel versus Fluorouracil or Capecitabine plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial. The Lancet, 393, 1948-1957.
https://doi.org/10.1016/S0140-6736(18)32557-1
[17]  Pietrantonio, F., Miceli, R., Raimondi, A., et al. (2019) Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability as a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 37, 3392-3400.
https://doi.org/10.1200/JCO.19.01124
[18]  Biagioni, A., Skalamera, I., Peri, S., et al. (2019) Update on Gastric Cancer Treatments and Gene Therapies. Cancer and Metastasis Reviews, 38, 537-548.
https://doi.org/10.1007/s10555-019-09803-7
[19]  Xue, K., Ying, X., Bu, Z., et al. (2018) Oxaliplatin plus S-1 or Capecitabine as Neoadjuvant or Adjuvant Chemotherapy for Locally Advanced Gastric Cancer with D2 Lymphadenectomy: 5-Year Follow-Up Results of a Phase II-III Randomized Trial. Chinese Journal of Cancer Research, 30, 516-525.
https://doi.org/10.21147/j.issn.1000-9604.2018.05.05

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133